Quality care measures for children proving difficult to quantify

Pediatric patients with BRAF V600E low-grade glioma as young as 1 year can now be treated with dabrafenib plus trametinib following its FDA approval.

All children included in the analysis achieved swallowing, oral nutrition, and airway protection outcomes.

Recent data revealed a 110% increase in speech disorder diagnoses for children aged 0 to 12 years in 2022, compared to the pre-pandemic era.

In a recent review, children with vaccination against human papillomavirus (HPV) initialized at a younger age were more likely to receive their full vaccination series.